Date: 2.4.2013
On 23rd February Immunotech Laboratory announced $2M funding approval from its associate Bulgarian Immunotech Partnership Company (Immunotech BG) for clinical trials of the firm’s patented HIV-AIDS medicine.
During the investigation, so-called IPF (Irreversible Pepsin Fraction) drugs will be examined with 50 patients involved. The medicine’s active substance, IPF, is a purified extract of porcine pepsin.
HIV infections are the most susceptible for treatment in their initial stages. However, the problem is that antiretroviral medicines cannot be applied then since drug resistance is very likely to arise. The possible solution is to use non-antiretroviral medicines, but such specifics are lacking...
...read more at
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Brno University of Technology - university of technology in Brno
Charles University - Charles University in Prague
Team develops promising new form of antibiotic that makes bacterial cells self-destruct
Low-cost method removes micro- and nanoplastics from water